Top
image credit: Adobe Stock

Traditional approaches to growth in biopharma are no longer sustainable

August 5, 2022

Category:

The pace of innovation in biopharma has rocketed over the last two years, with vaccines, new antivirals, and therapies delivered at an unprecedented pace. This has been a tough but ground-breaking period, but with this rapid rise in innovation comes risks. The industry is still relying on traditional vertical therapy areas (TAs) to drive expansion – these are no longer sustainable.

Through our recent report, Scientific innovations for more sustainable growth, we analysed over 300 M&A deals made by the world’s top 30 biopharma companies between 2010–2021. This revealed three core issues holding biopharma back – which the industry will need to overcome in order to pursue new growth paths:

Read More on Pharmaphorum